Reuters logo
BRIEF-Oncosec granted FDA fast track designation for ImmunoPulse IL-12 for treatment of metastatic melanoma
2017年2月27日 / 上午11点22分 / 8 个月内

BRIEF-Oncosec granted FDA fast track designation for ImmunoPulse IL-12 for treatment of metastatic melanoma

Feb 27 (Reuters) - Oncosec Medical Inc:

* Oncosec granted FDA fast track designation for immunopulse® IL-12 for the treatment of metastatic melanoma following progression on pembrolizumab or nivolumab

* Says clinical trial is planned to initiate in first half of 2017 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below